Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Gemcitabine
Overview
What is Gemcitabine?
Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl, USP is 2´-deoxy-2´,2´-difluorocytidine monohydrochloride (β-isomer).
The structural formula is as follows:
The empirical formula for Gemcitabine HCl, USP is CHFNO • HCl. It has a molecular weight of 299.66.
Gemcitabine HCl, USP is a white to off-white solid. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.
The clinical formulation is supplied as a sterile solution for intravenous single vial use only. Vials of gemcitabine injection contain either 200 mg, 1 g, or 2 g of gemcitabine HCl, USP (expressed as free base). Each mL contains equivalent of 38 mg of gemcitabine in Water for Injection, USP. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
What does Gemcitabine look like?
What are the available doses of Gemcitabine?
Gemcitabine Injection is a clear and colorless to light straw-colored solution available in sterile
single-dose vials containing:
What should I talk to my health care provider before I take Gemcitabine?
How should I use Gemcitabine?
Gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
Recommended Dose and Schedule
The recommended dose of gemcitabine injection is 1,000 mg/m as an intravenous infusion over
30 minutes on Days 1 and 8 of each 21-day cycle, in combination with carboplatin AUC 4 intravenously after gemcitabine injection administration on Day 1 of each 21-day cycle. Refer to carboplatin prescribing information for additional information.
Dose Modifications
Recommended gemcitabine injection dose modifications for myelosuppression are described in Table 1 and Table 2 . Refer to Dosage and Administration () for recommendations for non-hematologic adverse reactions.
Table 1: Dosage Reduction Guidelines for Gemcitabine Injection for Myelosuppression on Day of Treatment in Ovarian Cancer
Table 2: Gemcitabine Injection Dose Modification for Myelosuppression in Previous Cycle in Ovarian Cancer
What interacts with Gemcitabine?
Sorry No Records found
What are the warnings of Gemcitabine?
Sorry No Records found
What are the precautions of Gemcitabine?
Sorry No Records found
What are the side effects of Gemcitabine?
Sorry No records found
What should I look out for while using Gemcitabine?
Gemcitabine injection is contraindicated in patients with a known hypersensitivity to gemcitabine.
What might happen if I take too much Gemcitabine?
Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when a single dose as high as 5,700 mg/m was administered by intravenous infusion over 30 minutes every 2 weeks to several patients in a dose-escalation study.
How should I store and handle Gemcitabine?
Unopened vials of gemcitabine for injection, USP are stable until the expiration date indicated on the package when stored at controlled room temperature 20° to 25°C (68° to 77°F) and that allows for excursions between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature] [ ] Clindamycin Hydrochloride Capsules USP, 150 mgNDC 42292-018-20 – Unit dose blister packages of 100 (10 cards of 10 capsules each). Dispense in a tight container with child-resistant closure. Clindamycin Hydrochloride Capsules USP, 150 mgNDC 42292-018-20 – Unit dose blister packages of 100 (10 cards of 10 capsules each). Dispense in a tight container with child-resistant closure.
